Follow us Now on Telegram ! Get daily 10 - 12 Interesting Updates. Join our Telegram Channel https://t.me/OhWomen
Download Telegram App before Joining the Channel
: Morepen Laboratories Limited announces the launch of Empamore, a game-changing treatment for Type 2 Diabetes Mellitus (T2DM), Heart Failure with Reduced Ejection Fraction (HFrEF), and Chronic Kidney Disease (CKD). With India being the diabetes capital of the world and over 101 million people suffering from the disease, Empamore is poised to make a significant impact by offering high-quality treatment at an affordable price point, empowering millions of Indians to take control of their health.
Empamore: More Safety, More Efficacy, More Affordability
Morepen manufactures Empagliflozin (API) in its USFDA-approved facilities and already has European DMF. The launch of Empamore reflects Morepen’s 40 years of pharmaceutical excellence, providing a cost-effective alternative to leading brands while ensuring affordability without compromising quality. The product range includes:
* Empagliflozin (Empamore 10mg/25mg)
* Empagliflozin 12.5mg with Metformin 500/1000mg (Empamore M 500/1000mg)
Empagliflozin is a globally recognized SGLT2 inhibitor, widely used for diabetes management. With pre-diabetes cases in India rising to nearly 136 million and the diabetes market expected to grow at a CAGR of 10.9%, Morepen’s launch of Empamore comes at a crucial time to provide an affordable and effective solution.
Bridging the Healthcare Gap with Affordable Access
Speaking on the launch, Ashutosh Sharma, V.P. - Sales & Marketing, Morepen Laboratories, said:
“At Morepen, we are dedicated to democratizing healthcare by making world-class treatments accessible to all. With Empamore, we are providing a trusted, high-quality diabetes treatment at nearly 90% lower cost than existing brands, helping millions manage their condition effectively without financial strain. This aligns with our commitment to empower people to take charge of their health.”
Competitive Pricing & Nationwide Availability
The market price of Empagliflozin tablets has historically been high, making it inaccessible for many. With Morepen’s launch of Empamore at a fraction of the cost, the company aims to capture a significant share of the rapidly growing diabetes market in India, ensuring that quality treatment is no longer a privilege but a right for every patient.
Morepen’s Legacy in Diabetes Care
Morepen has been a pioneer in diabetes management solutions, having installed over 12.33 million glucometers and sold nearly 1.65 billion blood glucose strips. Empamore is a natural extension of Morepen’s commitment to empowering people with “Health in Your Hands”, offering them the tools they need to prevent, monitor, and treat diabetes effectively.
Empamore: Redefining Patient-Centric Diabetes Care
* Unmatched Affordability: Priced significantly lower than leading brands, ensuring access for all.
* Comprehensive Diabetes Solution: Beyond glycemic control, it addresses cardiovascular and renal complications.
* Global Quality Standards: Manufactured at Morepen’s USFDA-approved plant with DMF-grade quality, ensuring top-tier safety and efficacy.
* Innovative Packaging: Designed with perforated strip packaging for convenience and adherence, making daily management easier for patients.
Serving India & The World
With an extensive global footprint spanning 82 countries, Morepen continues to raise the bar in pharmaceutical innovation. The launch of Empamore reflects the company’s dedication to bringing affordable healthcare solutions to millions, not just in India but worldwide.
Source : PR Agency
